Lonza and Moderna Announce Further Collaboration For Drug Substance Manufacturing of COVID-19 Vaccine Moderna in the Netherlands
Lonza announced the expansion of its collaboration with Moderna. The expanded collaboration will further extend the manufacture of the drug substance for the COVID-19 Vaccine Moderna and provides for the installation of a new manufacturing line for drug substance production at Lonza’s Geleen (NL) site.

Symbolic image
pixabay.com
The new production line in Geleen (NL) will complement Lonza’s existing drug substance production network for COVID-19 Vaccine Moderna and deliver a crucial manufacturing step to increase overall drug substance output. As such, the new production line will contribute to the supply of up to an additional 300 million doses per year, at a 50ug dose, once operating at full capacity.
In May 2020, Lonza and Moderna announced a ten-year strategic collaboration agreement to enable the manufacture of Moderna’s COVID-19 vaccine and additional Moderna products in the future. Since then, Lonza has installed three production lines at its Visp (CH) site and one production line in Portsmouth (US). In April 2021, Lonza and Moderna entered a new agreement to add three further production lines at its Visp (CH) site.
The new production line in Geleen (NL) is expected to be operational by the end of 2021. Lonza will leverage its existing infrastructure in Geleen (NL) to provide fast build-out and ramp-up of operations.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
DakoCytomation and ViroNovative enter licensing agreement on Human Metapneumovirus
Augustino_Viccini_Special_School

Changes in the management of Hermann Waldner GmbH & Co. KG - New management structure
African-Caribbean_Leukaemia_Trust
Dyax Corp. and CSIRO Form Joint Antibody Discovery Collaboration in Oncology
Older_Women's_League
Sigma-Aldrich and Oxford BioMedica Pursue Protection of RNAi-Related Intellectual Property; File Suit Against Open Biosystems
Small, beautiful and additive-free - Radically new microscope commercialized

Vital metal - how can molybdenum be used biologically? - Mechanism of molybdenum insertase elucidated
